Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Lung cancer in India

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )

The global impact of the FDA's changing approval standards

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The global impact of the FDA's changing approval standards ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs...

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )

Durvalumab plus chemotherapy significantly improved OS in advanced biliary...

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South...

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )

Early treatment discontinuation and early oxaliplatin discontinuation for stage...

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in...

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco...

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr...

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more ( Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer )

More from ecancer